Gilbert Richard E, Connelly Kim, Kelly Darren J, Pollock Carol A, Krum Henry
University of Melbourne Department of Medicine, St. Vincent's Hospital, Victoria, Australia.
Clin J Am Soc Nephrol. 2006 Mar;1(2):193-208. doi: 10.2215/CJN.00540705. Epub 2005 Dec 7.
Heart failure (HF) is a major contributor to poor quality of life, a leading cause of hospitalization, and cause of premature death. Both kidney disease and diabetes are major and independent risk factors for the development of heart failure, such that individuals with diabetic nephropathy are at especially high risk. Such patients not only are likely to have coronary artery disease and hypertension but also are likely to have diabetic cardiomyopathy, a distinct pathologic entity that is more closely associated with the microvascular than the macrovascular complications of diabetes. In addition to a better understanding of the epidemiology of HF, advances in noninvasive imaging have highlighted the importance of early cardiac dysfunction in diabetes and the high prevalence of HF with preserved left ventricular systolic function. Although significant renal dysfunction is usually an exclusion criterion in HF trials, diabetes is often a prespecified subgroup so that subanalyses of large multicenter clinical trials do provide some guidance in therapeutic decision-making. However, further therapies for both HF and nephropathy in diabetes clearly are needed, and a number of new therapeutic strategies that target both disorders have already entered the clinical arena.
心力衰竭(HF)是导致生活质量低下的主要因素,是住院的主要原因及过早死亡的病因。肾脏疾病和糖尿病都是心力衰竭发生的主要独立危险因素,因此患有糖尿病肾病的个体风险尤其高。这类患者不仅可能患有冠状动脉疾病和高血压,还可能患有糖尿病性心肌病,这是一种独特的病理实体,与糖尿病的微血管并发症而非大血管并发症联系更为紧密。除了对心力衰竭流行病学有了更好的了解之外,无创成像技术的进步突出了糖尿病早期心脏功能障碍的重要性以及左心室收缩功能保留的心力衰竭的高患病率。尽管严重肾功能不全通常是心力衰竭试验的排除标准,但糖尿病常常是预先指定的亚组,因此大型多中心临床试验的亚组分析确实能为治疗决策提供一些指导。然而,显然需要针对糖尿病患者的心力衰竭和肾病的进一步治疗方法,并且一些针对这两种疾病的新治疗策略已经进入临床阶段。